Sanofi has finalized its takeover of Vigil Neuroscience for roughly $470 million, acquiring all outstanding shares at $8 each and issuing a $2-pe ...

Paris Thursday, August 7, 2025, 10:00 Hrs [IST] Sanofi announces the completion of its acquisition of Vigil Neuroscience, I ...

Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”). This acquisition ...

Sanofi finalise l’acquisition de Vigil Neuroscience, Inc. Paris, le 6 août 2025. Sanofi annonce la finalisation de l’acquisition de Vigil Neuroscience, Inc. (« Vigil »). Cette acquisition renforce le ...

Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”). This acquisition ...

VGP NV (‘VGP’ or ‘the Group’), a European provider of high-quality logistics and semi-industrial real estate, announces the details for the webcast to review its financial results for the first half ...

Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.

Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease progression and cognitive decline.

French pharmaceuticals giant Sanofi has agreed to acquire privately-owned British biotech firm, Vicebio, in a deal worth up to $1.6billion (£1.2billion).

Detailed price information for Vigil Neuroscience Inc (VIGL-Q) from The Globe and Mail including charting and trades.

Vigil Neuroscience , Inc. (NASDAQ:VIGL) announced Thursday that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its planned merger with Sanofi (NASDAQ:SNY) has ...